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Abstract: Purpose: Ultrasound-guided biopsy (US biopsy) with 10-12 cores has a suboptimal sensi-
tivity for clinically significant prostate cancer (sigPCa). If US biopsy is negative, magnetic resonance
imaging (MRI)-guided biopsy is recommended, despite a low specificity for lesions with score 3-5 on
Prostate Imaging Reporting and Data System (PIRADS). Screening and biopsy guidance using an imag-
ing modality with high accuracy could reduce the number of unnecessary biopsies, reducing side effects.
The aim of this study was to assess the performance of positron emission tomography/MRI with 68Ga-
labeled prostate-specific membrane antigen (PSMA-PET/MRI) to detect and localize primary sigPCa
(ISUP grade group 3 and/or cancer core length ฀ 6 mm) and guide biopsy. Methods: Prospective,
open-label, single-center, non-randomized, diagnostic accuracy study including patients with suspected
PCa by elevation of prostate-specific antigen (PSA) level and a suspicious lesion (PIRADS ฀3) on mul-
tiparametric MRI (mpMRI). Forty-two patients underwent PSMA-PET/MRI followed by both PSMA-
PET/MRI-guided and section-based saturation template biopsy between May 2017 and February 2019.
Primary outcome was the accuracy of PSMA-PET/MRI for biopsy guidance using section-based satu-
ration template biopsy as the reference standard. Results: SigPCa was found in 62% of the patients.
Patient-based sensitivity, specificity, negative and positive predictive value, and accuracy for sigPCa
were 96%, 81%, 93%, 89%, and 90%, respectively. One patient had PSMA-negative sigPCa. Eight
of nine false-positive lesions corresponded to cancer on prostatectomy and one in six false-negative le-
sions was negative on prostatectomy. Conclusion: PSMA-PET/MRI has a high accuracy for detecting
sigPCa and is a promising tool to select patients with suspicion of PCa for biopsy. Trial registration:
This trial was retrospectively registered under the name ”Positron Emission Tomography/Magnetic Res-
onance Imaging (PET/MRI) Guided Biopsy in Men with Elevated PSA” (NCT03187990) on 06/15/2017
( https://clinicaltrials.gov/ct2/show/NCT03187990 ). Keywords: Imaging-guided biopsy; PET/MR;
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Abstract
Purpose Ultrasound-guided biopsy (US biopsy) with 10–12 cores has a suboptimal sensitivity for clinically significant prostate cancer
(sigPCa). If US biopsy is negative, magnetic resonance imaging (MRI)–guided biopsy is recommended, despite a low specificity for
lesions with score 3–5 on Prostate Imaging Reporting and Data System (PIRADS). Screening and biopsy guidance using an imaging
modality with high accuracy could reduce the number of unnecessary biopsies, reducing side effects. The aim of this study was to
assess the performance of positron emission tomography/MRI with 68Ga-labeled prostate-specific membrane antigen (PSMA-PET/
MRI) to detect and localize primary sigPCa (ISUP grade group 3 and/or cancer core length ≥ 6 mm) and guide biopsy.
Methods Prospective, open-label, single-center, non-randomized, diagnostic accuracy study including patients with suspected
PCa by elevation of prostate-specific antigen (PSA) level and a suspicious lesion (PIRADS ≥3) on multiparametric MRI
(mpMRI). Forty-two patients underwent PSMA-PET/MRI followed by both PSMA-PET/MRI-guided and section-based satu-
ration template biopsy betweenMay 2017 and February 2019. Primary outcomewas the accuracy of PSMA-PET/MRI for biopsy
guidance using section-based saturation template biopsy as the reference standard.
Results SigPCa was found in 62% of the patients. Patient-based sensitivity, specificity, negative and positive predictive value,
and accuracy for sigPCa were 96%, 81%, 93%, 89%, and 90%, respectively. One patient had PSMA-negative sigPCa. Eight of
nine false-positive lesions corresponded to cancer on prostatectomy and one in six false-negative lesions was negative on
prostatectomy.
Conclusion PSMA-PET/MRI has a high accuracy for detecting sigPCa and is a promising tool to select patients with suspicion of
PCa for biopsy.
Trial registration This trial was retrospectively registered under the name “Positron Emission Tomography/Magnetic Resonance
Imaging (PET/MRI) Guided Biopsy in Men with Elevated PSA” (NCT03187990) on 06/15/2017 (https://clinicaltrials.gov/ct2/
show/NCT03187990).
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Introduction
Assessment of histological tumor grade on biopsy is needed for
diagnosis and risk classification of prostate cancer (PCa). The
updated European Association of Urology (EAU) guideline
recommends ultrasound-guided systematic prostate biopsy
(US biopsy) in patients with suspicion of PCa [1, 2].
Magnetic resonance imaging (MRI)–guided biopsy is consid-
ered for cases in which no cancer was detected [2]. The
PROMIS trial revealed sensitivity of only 48% for their primary
definition of clinically significant cancer (sigPCa) using 10–12
cores US biopsy and suggested that, instead, multiparametric
MRI (mpMRI) should be used to reduce the number of unnec-
essary biopsies. However, if all lesions with a score ≥ 3 on
Prostate Imaging Reporting and Data System (PIRADS) are
targeted, the specificity of mpMRI is only 41% [3]. Several
other studies also showed superior detection rates of sigPCa
in MRI-guided biopsy compared to US biopsy [4–7].
Nevertheless, false-negative results or histological upgrade after
surgery are found in 21% of patients [8–10]. The most reliable
method to reduce undersampling and false-negative results is
transperineal saturation biopsy (template biopsy) with samples
taken from all 20 Barzell zones, leading to organ coverage of
approximately 95% [10]. Screening and imaging-guided biopsy
could potentially reduce side effects of saturation prostate biop-
sies [11], but recent studies suggest that a template-based sys-
tematic approach should not be omitted despite mpMRI [6, 12].
Positron emission tomography (PET)/MRI targeting
prostate-specific membrane antigen (PSMA) could be an ideal
technique to improve the accuracy of imaging-guided biop-
sies, combining the high sensitivity and specificity of PSMA-
PET for PCa with the high anatomical contrast and spatial
resolution of MRI [13–15]. Despite promising results in
PSMA-PET/computed tomography (CT) for biopsy targeting
[16], with an accuracy of 80.6% for sigPCa [17], the diagnos-
tic accuracy of PSMA-PET/MRI-guided biopsy has not yet
been prospectively assessed. Therefore, the aim of this study
is to assess the performance of 68Ga-PSMA-11 PET/MRI
(PSMA-PET/MRI) to detect and localize primary sigPCa for
accurate prostate biopsy guidance.
Patients and methods
Study design
The study was designed as an open-label, single-center, non-
randomized, prospective diagnostic accuracy study including
patients with suspected PCa. Patients without biopsy-proven
sigPCa but suspicion of cancer due to persistently elevated
prostate-specific antigen (PSA) (PSA > 2.5 ng/ml if age 30–
50 years and PSA > 4 ng/ml if age 50–80 years) and at least
one suspicious lesion on mpMRI clinical report (PIRADS ≥3)
were included. All patients underwent PSMA-PET/MRI
followed by both PSMA-PET/MRI-guided and section-
based saturation template biopsy of the prostate between
May 2017 and February 2019. Exclusion criteria were age <
30 and > 80, previous biopsy within 8 weeks prior to imaging,
previous pelvic irradiation, prostatectomy, transurethral resec-
tion of the prostate (TURP) or androgen deprivation hormonal
therapy (ADT), and any contra-indication to MRI or prostate
biopsy as well active urinary tract infection or indwelling
catheter. PSMA-PET/MRI and biopsy were performed with
an interval of up to 30weeks frommpMRI (median 2.7weeks,
IQR 0.4–12). Figure 1 illustrates patient selection. This study
was approved by the institutional review board (BASEC Nr:
2017-00016), was carried out in accordance with the
Declaration of Helsinki, and is registered in the international
trial registry ClinicalTrials.gov (NCT03187990).
68Ga-PSMA-11 PET/MRI imaging acquisition and
analysis
All patients underwent a pelvic PET/MRI on a hybrid scanner
(SIGNA PET/MR, GE Healthcare, Waukesha, WI, USA)
Fig. 1 Patient selection and inclusion in the study
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60 min after injection of 85 MBq of 68Ga-PSMA-11. A 15-
min frame over the prostate was recorded, allowing reducing
the dose since patients without confirmed cancer were includ-
ed. For biopsy targeting, suspected lesions were delineated on
PSMA-PET/MRI by a double-board-certified nuclear medi-
cine physician and radiologist, specialist in pelvic imaging,
with 10 and 5 years of experience (IAB,MM), with a maxi-
mum of three target lesions. Imaging protocol and analysis are
given in the supplements (Online Resource 1).
Biopsy
Biopsies were performed under general anesthesia by specialized
urologists with US-MRI software fusion (BiopSee®). Axial
fused PSMA-PET/MRI images in DICOM format were
uploaded to BiopSee® instead of T2w MRI sequences.
Standard transperineal template biopsy with number of cores
adapted to prostate volume as well as PSMA-PET/MRI-targeted
biopsy was performed with a maximum of three cores per target
lesion (Online Resource 2). Patients with no suspicious uptake
on PSMA-PET/MRI or with discordant lesions between PSMA-
PET/MRI and mpMRI underwent template biopsy and the urol-
ogist was free to target any suspicious lesion on mpMRI.
Clinically significant cancer definition
SigPCa was defined as International Society of Urological
Pathology (ISUP) grade group 3 and/or cancer core length ≥
6 mm [18]. Conversely, clinically insignificant cancer
(insigPCa) was defined as ISUP 1 or 2 lesions with cancer
core length < 6 mm. Biopsies with the latter characteristics
were classified as negative for further analysis. Results based
on other definition of sigPCa (ISUP ≥2) are in Table S3
(Online Resource 1).
Reference standard
Results of PSMA-PET/MRI-targeted biopsies were compared
to template biopsies regarding presence of sigPCa on histopa-
thology. All patients classified as having a false-positive or
false-negative 68Ga-PSMA-11 PET/MRI result had the biopsy
samples, or radical prostatectomy (RPE) specimens if avail-
able, reevaluated on histopathology for possible explanations
including PSMA immunohistochemistry (IHC). Biopsies and
RPE specimens were evaluated by two board-certified genito-
urinary pathologists (NR, JR) with 8–10 years of experience.
Data analysis
Study results were analyzed using descriptive statistics and
frequency tables in Excel (Excel2016, Microsoft, USA).
Accuracy was assessed on 2 × 2 contingency tables on patient
and lesion basis. For lesion-based analysis, the number of
lesions was defined as number of PSMA-positive lesions
added to number of PSMA-negative lesions with sigPCa
found on biopsy. For patient-based analysis in patients with
more than one lesion and different classifications (for exam-
ple, one true-positive and one false-negative lesion), we con-
sidered whether PSMA-PET/MRI correctly staged the patient
regarding the presence or absence of sigPCa according to
Table S1 (Online Resource 1). We also assessed patient-
based accuracy for PET/MRI-targeted cores.
Results
General
Forty-nine patients met the inclusion criteria and were includ-
ed between May 2017 and January 2020. Seven patients with-
drew participation before the PSMA-PET/MRI scan or the
biopsy was performed; therefore, data from 42 patients were
analyzed (descriptive characteristics in Table 1). Median in-
terval between PSMA-PET/MRI and biopsy was 12 days (in-
terquartile range (IQR) 6–18).
Biopsy
Based on template and targeted biopsy, 26 of 42 (62%) pa-
tients had sigPCa. While there was no malignancy in seven of
42 patients (17%), in the remaining nine patients (21.4%),
cancer detected on biopsy did not meet the criteria of
sigPCa. Fifteen cases of sigPCa were detected by both tem-
plate and targeted biopsies (58%, 15/26), nine only by tem-
plate (35%) and two only by targeted (8%). Two cases of
insigPca were detected by both biopsy methods (22%, 2/9),
six only by template (67%) and one only by targeted. Table 2
and Fig. 2 show the distribution of sigPCa, insigPCa, and no
disease, in correlation to PIRADS, ISUP, and PSMA-PET/
Table 1 Characteristics of the patients at inclusion in the study (n = 42)
Characteristics Value
Age at scan (years)
Mean±SD 64±6
Median (IQR) 65 (59–68)
PSA at time of PET scan (ng/ml)
Mean±SD 10±7.4





SD= standard deviation; IQR = interquartile range
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MRI result. Eighteen patients had one lesion, seven patients
had two, and one patient had three lesions, resulting in 35
sigPCa lesions in total. The median number of positive cores
per patient was three (IQR 2–6). The median number of sam-
ples taken per patient was 43 (IQR 36–44). Eight patients
(19%, 8/42) had biopsy procedure complications, none life-
threatening. Six patients presented to the emergency depart-
ment for acute urinary retention, one patient had
postinterventional bleeding with need of catheter irrigation,
and one patient with anesthesia complications was admitted
for observation and released the day after.
68Ga-PSMA-11 PET/MRI
Table 3 shows sensitivity, specificity, positive predictive value
(PPV), negative predictive value (NPV), and accuracy of
PSMA-PET/MRI per patient and per lesion. PSMA-PET/MRI
was positive in 28 patients (66.7%, 28/42), of which 25 had
sigPCa on biopsy (89%, 25/28) and negative in 14 patients
(33.3%, 14/42), of which only one had sigPCa (7%, 1/14)
(Figs. 2b and 3a). Nineteen patients had one PSMA-positive
lesion, eight patients had two lesions, and one patient had three
lesions, resulting in 38 PSMA-positive lesions. One patient had a
lesion without PSMA uptake but clear PIRADS 5 features on
MRI, confirmed as sigPCa by MRI-targeted biopsy and classi-
fied as negative PSMA-PET/MRI for further analysis. Figure 3b
shows PSMA-PET/MRI results in relation to PIRADS.
The accuracy of PSMA-targeted cores was lower com-
pared to PSMA-PET/MRI imaging findings. In eight cases
with PSMA uptake in the sigPCa lesion, the three target
needles were negative, but additional adjacent template
needles confirmed sigPCa.
Per lesion, 44 lesions were detected in 29 patients (38 on
PSMA-PET/MRI and 35 on biopsy, with 29 concordant le-
sions). Six sigPCa lesions and 24 insigPCa lesions were not
detected by PSMA-PET/MRI.
Table 2 Distribution of






as ISUP grade ≥ 3 and/or
cancer core length ≥
6 mm. Seven patients
had no cancer on biopsy
sigPCa insigPCa
ISUP
1 1 (4%) 3 (33%)
2 6 (23%) 6 (67%)
3 9 (34%) –
4 8 (31%) –
5 2 (8%) –
Total 26 9
sigPCa = clinically significant prostate
cancer; insigPCa = clinically insignificant
prostate cancer
Fig. 2 Distribution of patients
with clinically significant prostate
cancer (sigPCa), clinically
insignificant prostate cancer
(insigPCa), and no evidence of
disease on biopsy in correlation to
PIRADS classification on
multiparametric resonance
magnetic imaging (a) and 68Ga-
PSMA-11 PET/MRI result (b)
Table 3 Performance of PSMA-PET/MRI for biopsy guidance, given








Sensitivity 96% (25/26) 65% (17/26) 83% (29/35)
Specificity 81% (13/16) 81% (13/16) –
PPV 89% (25/28) 61% (17/28) 76% (29/38)
NPV 93% (13/14) 93% (13/14) –
Accuracy 90% (38/42) 71% (30/42) –
PPV = positive predictive value; NPV = negative predictive value. For
the targeted core analysis, values were calculated as if patients with a
negative PSMA-PET/MRIwere not submitted to biopsy and patients with
a positive PSMA-PET/MRI underwent only PSMA-PET/MRI-targeted
biopsy. Lesion-based specificity and NPV were not calculated since pa-
tients with negative PSMA-PET/MRI and no significant cancer on biopsy
have, per definition, no lesion
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False-positive PSMA-PET/MRI
Three patients had a false-positive PSMA-PET/MRI, but
insigPCa on biopsy in at least one of the PSMA uptake areas
(ISUP grade group 2 with cancer length of 1.5–5 mm).
Relevant cancer was confirmed on RPE specimen in all three
cases (Fig. 4).
Per lesion, nine lesions were false-positive (Online Resource
3). In all patients, RPE was available and showed cancer in
eight lesions (Table 4). In the case without cancer, additional
pathology workup showed clear PSMA overexpression on
IHC, but no benign or malignant alterations. Interval between
biopsy and RPE in these patients ranged from 1 to 3.8 months.
False-negative PSMA-PET/MRI
68Ga-PSMA-11 PET/MRI was false-negative in one patient
with sigPCa, who had two positive cores with ISUP grade
group 2 and lengths of 9 and 10 mm. Despite no PSMA
uptake, the lesion was easily appreciated on T2- and
diffusion-weighted sequences of the MRI component (Fig. 5).
Per lesion, six were false-negatives (Online Resource 4). In
four lesions, ISUP grade was low or tumor volume small (up to
3mm) on biopsy. In one case, there was no cancer on RPE in the
corresponding location of the positive biopsy core (Table 4).
One lesion with positive cores of ISUP grade group 4 (6 mm)
was downgraded to ISUP grade 2 on RPE and in one lesion
(ISUP 2, 10 mm) biopsy cores stained for PSMA on IHC
showed a PSMA-negative tumor (Fig. 5). The interval between
biopsy and RPE in these patients ranged from 1.4 to 3.7 months.
Discussion
PSMA-PET/MRI showed a patient-based accuracy of 90% for
detecting sigPCa in our cohort, with a sensitivity of 96% and
specificity of 81%. This is higher than the mpMRI accuracy
reported in most studies using template biopsy as reference
standard [19], including the PROMIS trial, which reported
sensitivity and specificity of 93% and 41%, respectively [3].
Our improved specificity was mainly due to PSMA-PET mit-
igating false-positive mpMRI PIRADS 3 and 4 lesions har-
boring no sigPCa (Fig. 3b). The PROMIS authors conclude
Fig. 3 Distribution of patients
with clinically significant prostate
cancer (sigPCa), clinically
insignificant prostate cancer
(insigPCa), and no evidence of
disease on biopsy according to
68Ga-PSMA-11 PET/MRI results
(a) and according to 68Ga-PSMA-
11 PET/MRI results in correlation
to PIRADS classification on
multiparametric resonance mag-
netic imaging (b). The single
false-negative case and the three
false-positive cases shown in part
“a” are shown in part “b” under
PIRADS 5/negative PSMA-PET/
MRI and PIRADS 3/positive
PSMA-PET/MRI (two cases) and
4/positive PSMA-PET/MRI (one
case), respectively
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that screening by mpMRI prior to biopsy could reduce the
number of unnecessary biopsies. Our study suggests PSMA-
PET/MRI could further improve on mpMRI patient selection.
In our cohort, 16 patients (38%) without sigPCa underwent
biopsy based on equivocal or suspicious lesions on mpMRI
(PIRADS 3 to 5). Omitting biopsy in patients with negative
PSMA-PET/MRI would have spared 13 (13/16, 81%), with-
out missing any patient with sigPCa. Only one patient had a
false-negative PSMA-PET result; however, his ISUP 2 tumor
would not have been missed due to clear PIRADS 5 features
on MRI. The tumor was PSMA-negative on IHC, which is in
accordance with the reported rate of around 5% of PSMA-
negative tumors in the literature [20]. For the three patients
with false-positive PSMA-PET/MR results, insigPCa was
present on template biopsy, and cancer with Gleason 4 pattern
was confirmed on RPE in each case.
Interestingly, despite PET findings confirmed by biopsy in
90% of the cases, the accuracy of 71% with a sensitivity of
65% for PET-targeted biopsy shows that some of the sigPCa
lesions seen on PET are actually missed by the three targeted
cores. This was already reported by van der Leest et al. [9] in a
study comparing transrectal US-guided biopsy versus MRI-
guided biopsy. They found that positive TRUS cores were
obtained from the mpMRI lesion area or its neighboring and
suggested that four additional perilesional cores greatly im-
proved sigPCa detection with MRI-guided biopsy. They
concluded that the majority of sigPCa missed by targeted bi-
opsy was probably due to sampling errors related to spatial
heterogeneity of the tumor [9].
False-negative and false-positive lesions in our study were
often lesions with borderline characteristics regarding clinical
significance. The lower PSMA expression in Gleason pattern
3 compared to 4 has been demonstrated on IHC [20–22] and
our results probably reflect it: most false-negative lesions
corresponded to low-grade groups (ISUP 1 and 2) or small
volume tumors and, in only one case, a significant PSMA-
negative tumor. Omitting template biopsy in our cohort would
leave undetected six sigPCa, but also 24 lesions with
insigPCa, mitigating overdiagnosis. On the other hand, eight
of nine false-positive lesions based on biopsy were insigPCa,
with only one showing no cancer on RPE specimen. This case
was previously published as a case report with extensive his-
topathology workup excluding inflammation, pre-cancerous
lesions, or other malignancies [23]. Therefore, template and
targeted biopsies were false-negative for significant disease
for eight lesions.
The definition of sigPCa is not standardized among cen-
ters; therefore, we chose the definition used in the PROMIS
trial [3] to allow a direct comparison of our results. We rec-
ognize that other definitions can be found in the literature and
that more recent guidelines of the EAU suggest considering
any ISUP grade group 2 biopsy as sigPCa [1, 2]. Incorporating
Fig. 4 All three patients with a false-positive PSMA-PET/MRI. From left
to right, prostate MRI sequences T2-weighted and diffusion-weighted
images (b value 1000), fused PET/MRI, representative pathology map
with biopsy results, and radical prostatectomy (RPE) specimen with tu-
mor outlined on hematoxylin and eosin staining (H&E) and PSMA-IHC
(overview and magnification). Bars represent 2.5 mm in the H&E and
PSMA-IHC images and 100 μm in the PSMA-IHC magnified images.
Blue dots in the pathology map correspond to location of needles with
clinically insignificant cancer diagnosed. a 67-year-old patient, with a
PSA of 7.3 ng/ml and a PIRADS 4 lesion on mpMRI. PSMA-PET/
MRI shows one targeted lesion (arrow) in the posterior right peripheral
zone, where biopsy found ISUP grade group 2 tumor with up to 1.5-mm
length. RPE specimen shows a PSMA-positive ISUP grade group 3 tu-
mor in the PSMA uptake area. b 65-year-old patient, with a PSA of
7.18 ng/ml and a PIRADS 3 lesion on mpMRI. PSMA-PET/MRI shows
one targeted lesion (arrow) in the anterior zone, where biopsy found ISUP
grade group 2 tumor with up to 1.5-mm length. RPE specimen shows a
PSMA-positive ISUP grade group 2 tumor in the PSMA uptake area. c
65-year-old patient, with a PSA of 48.5 ng/ml and a PIRADS 3 lesion on
mpMRI. PSMA-PET/MRI shows two targeted lesions (arrows) in the
transition zone corresponding on biopsy to ISUP grade group 2 tumor
up to 5 mm length, and in the posterior left peripheral zone, where biopsy
was negative. RPE specimen shows a PSMA-positive ISUP grade group
3 tumor in the PSMA uptake area of the posterior left peripheral zone
Eur J Nucl Med Mol Imaging
Table 4 Findings on PET (SUVmax), biopsy, and radical prostatectomy
(RPE) specimen of the false-positive and false-negative lesions on
PSMA-PET/MRI. PSMA-PET/MRI image of each lesion can be seen
in the correspondent supplementary figure (Online Resources 3 for Fig.
S2 and 4 for Fig. S3) showed in the first column
Fig. SUVmax Biopsy RPE specimen
Finding ISUP Length (mm) Finding ISUP
False-positive lesions*
Pat. 03 S2 a 7.9 ASAP – – PSMA overexpression –
Pat. 24 S2 b 5.3 Inflammation – – Cancer 3
Pat. 30 S2 c 5.4 insigPCa 2 1.0 Cancer 2
Pat. 32 S2 d 12.9 insigPCa 2 2.0 Cancer 2
Pat. 33 S2 e 9.4 insigPCa 2 1.5 Cancer 3
Pat. 35 S2 f 4.4 insigPCa 2 5.0 Cancer 2
Pat. 35 S2 g 5.7 None – – Cancer 3
Pat. 38 S2 h 10.1 None – – Cancer 2
Pat. 42 S2 i 8 insigPCa 2 1.5 Cancer 2
False-negative lesions*
Pat. 05 S3 a – sigPCa 1 6.0 Not available –
Pat. 07 S3 b – sigPCa 3 1.0 No cancer –
Pat. 16 S3 c – sigPCa 3 3.0 Cancer 3
Pat. 26 S3 d – sigPCa 4 6.0 Cancer 2
Pat. 32 S3 e – sigPCa 2 6.0 Cancer 2
Pat. 39 S3 f – sigPCa PSMA-negative 2 10.0 Not available –
*Based on biopsy findings
ASAP = atypical small acinar proliferation; insigPCa = clinically insignificant prostate cancer; sigPCa = clinically significant prostate cancer;
SUVmax =maximum standardized uptake value
Fig. 5 The only patient with a false-negative PSMA-PET/MRI in our
cohort. A 62-year-old patient with a PSA of 11.38 ng/ml. Top images
from left to right are prostate MRI sequences T2-weighted and diffusion-
weighted images and fused PET/MRI showing a PIRADS 5 lesion in the
anterior transition zone (arrows) with no PSMA uptake. Bottom left im-
age shows the representative pathology map with biopsy results including
two cores with clinically significant cancer in the lesion area (red dots,
ISUP grade group 2 tumor with length up to 10mm) and many cores with
clinically insignificant cancer (blue dots). Remaining bottom images
show one of the biopsy cores with clinically significant cancer. The tumor
is outlined in hematoxylin and eosin staining (H&E) and PSMA-IHC
(overview and magnification), showing a virtually PSMA-negative tu-
mor. Bars represent 2.5 mm in the H&E and PSMA-IHC images and
100 μm in the PSMA-IHC magnified image
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this cutoff, we would have had only one false-positive PET in
our cohort on per-patient analysis, but four false-negative PET
scans. Therefore, we also give the results using this other
definition of sigPCa in Tables S2 and S3 (Online Resource 1).
There is sparse literature on PSMA-PET/CT-guided biopsy.
Recently, PSMA-PET/CT was compared, for biopsy purposes,
to micro-ultrasound, a novel imaging technique with promising
results when added to mpMRI [24]. PSMA-PET/CT yielded an
accuracy of 83% versus 61% of micro-ultrasound [25]. No study
so far compared PSMA-PET/CT to PET/MRI for biopsy guid-
ance. In our limited experience (anecdotal data not included in
present study), delineating the prostate and PSMA-positive le-
sions on non-contrast-enhanced CT using US-fusion-software is
feasible but cumbersome. In a study with 31 patients, sensitivity
and specificity for sigPCa of PSMA-PET/CT-guided biopsy was
100% and 68% [17]. The higher sensitivity and lower specificity
compared to our study may be explained by the approach to
biopsy the prostate area with highest PSMA uptake if no suspi-
cious lesion was reported. This probably led to false-positives,
which could be ruled out byMRI but not by CT, such as activity
in the central zone [26]. Another study found a region-based
sensitivity of PET/CT for sigPCa of 61%, lower than our
lesion-based sensitivity (83%). However, patients did not under-
go mpMRI so no insights on PET/CT limitations compared to
PET/MRI could be drawn [27]. A prospective study showed
higher detection rate of sigPCa for PET/CT compared to 12-
core TRUS biopsy; however, biopsies were performed within
the CT scanner, and again mpMRI was not performed routinely
[28]. In a study with 97 patients that compared PSMA-PET/CT
with mpMRI, PSMA-PET/CT identified 25% of patients with
Gleason 7 tumors missed bympMRI [29]. Due to their inclusion
criteria, around half of the patients that were biopsied had contra-
indications to mpMRI or PIRADS 1 or 2; what makes it difficult
to compare their results to ours but rather offers nice complemen-
tary data. Interestingly, these results are similar to the results
found by the same group in a smaller cohort using 11C-
Choline PET/CT, with 26% of patients with Gleason 7 tumors
detected by PET in patients with negative or contra-indication to
mpMRI [30]. Advantages of PET/MRI over PET/CT are that
surgeons are already used to delineate prostate and target lesions
based on MRI and that they can target lesions by both PSMA-
PET and MRI in case of discordance. That a combination of
these both methods could further improve the sensitivity for de-
tecting PCa was already shown by Eiber et al. [13]. While PET/
MRI profits from the higher soft tissue contrast, studies
performing head-to-head comparisons are needed to investigate
whether this offsets the higher general availability and lower cost
of PET/CT. Moreover, post hoc image fusion of MRI and
PSMA-PET (from PET/CT) may be a viable option for centers
without a dedicated PET/MRI device.
Despite the good coverage of template biopsy, absence of
RPE specimen as reference standard in some cases is a limita-
tion of this study. Given that RPE specimen were not available
for all patients, we opted to use RPE results only to investigate
false-positive or false-negative lesions on PSMA-PET/MRI.
Another limitation is pre-selection of patients based on
mpMRI results. The aim of this proof-of-mechanism study
was to assess whether PSMA-PET/MR could add value to
mpMRI. Given that the probability of sigPCa in patients with
PIRADS 1–2 is very low, we opted to exclude those patients in
a first step. However, this limits the conclusion about the accu-
racy of PET scans in an mpMRI naïve population.
Conclusions
PSMA-PET/MRI has a high accuracy for detecting sigPCa and
is a promising tool to select patients for biopsy aswell as to guide
it, with the potential to substantially reduce unnecessary biopsies
compared to mpMRI and might even improve the detection of
sigPCa in comparison to systematic template biopsies.
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